{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/AGIO/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-17T03:41:55.209Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":9686,"canonical_name":"AGIOS PHARMACEUTICALS, INC.","cik":"0001439222","uei":null,"lei":null,"duns":null,"ticker":"AGIO"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"clinical":8,"sec":39},"count":47,"timeline":[{"ts":"2026-10-05","kind":"clinical.trial","reporter":"Agios Pharmaceuticals, Inc.","title":"A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera","security_title":"PHASE2,PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07859423","excerpt":"[\"Polycythemia Vera\"]","importance":60},{"ts":"2026-09-28","kind":"clinical.trial","reporter":"Agios Pharmaceuticals, Inc.","title":"A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07656415","excerpt":"[\"Sickle Cell Disease\"]","importance":60},{"ts":"2026-08-06","kind":"sec.filing","form_type":"4","title":"4 — AGIOS PHARMACEUTICALS, INC. — 2026-08-06","url_slug":"/sec/cik-0001439222/4/0001439222-26-000120","accession_number":"0001439222-26-000120","importance":30},{"ts":"2026-08-04","kind":"sec.insider.s","reporter":"Gheuens Sarah","title":"Chief Medical Officer","shares":30000,"price_per_share":30.48,"usd_value":914400,"security_title":"Common stock","importance":35.9144},{"ts":"2026-08-04","kind":"sec.filing","form_type":"144","title":"144 — AGIOS PHARMACEUTICALS, INC. — 2026-08-04","url_slug":"/sec/cik-0001439222/144/0001950047-26-007592","accession_number":"0001950047-26-007592","importance":30},{"ts":"2026-08-03","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — AGIOS PHARMACEUTICALS, INC. — 2026-08-03","url_slug":"/sec/cik-0001439222/schedule-13g-a/0000908834-26-000367","accession_number":"0000908834-26-000367","importance":30},{"ts":"2026-07-30","kind":"sec.filing","form_type":"10-Q","title":"10-Q — AGIOS PHARMACEUTICALS, INC. — 2026-07-30","url_slug":"/sec/cik-0001439222/10-q/0001439222-26-000118","accession_number":"0001439222-26-000118","importance":45},{"ts":"2026-07-30","kind":"sec.filing","form_type":"8-K","title":"8-K — AGIOS PHARMACEUTICALS, INC. — 2026-07-30","url_slug":"/sec/cik-0001439222/8-k/0001439222-26-000115","accession_number":"0001439222-26-000115","importance":35},{"ts":"2026-07-10","kind":"sec.filing","form_type":"4","title":"4 — AGIOS PHARMACEUTICALS, INC. — 2026-07-10","url_slug":"/sec/cik-0001439222/4/0001439222-26-000112","accession_number":"0001439222-26-000112","importance":30},{"ts":"2026-07-08","kind":"sec.insider.a","reporter":"Backstrom Jay T.","title":null,"shares":1447,"price_per_share":0,"usd_value":0,"security_title":"Common stock","importance":15},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — AGIOS PHARMACEUTICALS, INC. — 2026-07-02","url_slug":"/sec/cik-0001439222/4/0001439222-26-000110","accession_number":"0001439222-26-000110","importance":30},{"ts":"2026-07-01","kind":"sec.form144","reporter":"Gheuens Sarah","title":"Officer","shares":4007,"usd_value":150503,"security_title":"Common Stock","approx_sale_date":"2026-07-01","accession_number":"0001439222-26-000108","importance":40.030100584},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Gheuens Sarah","title":"Chief Medical Officer","shares":4007,"price_per_share":37.56,"usd_value":150503,"security_title":"Common stock","importance":35.15050292},{"ts":"2026-07-01","kind":"sec.filing","form_type":"144","title":"144 — AGIOS PHARMACEUTICALS, INC. — 2026-07-01","url_slug":"/sec/cik-0001439222/144/0001439222-26-000108","accession_number":"0001439222-26-000108","importance":30},{"ts":"2026-07-01","kind":"sec.insider.m","reporter":"Gheuens Sarah","title":"Chief Medical Officer","shares":8375,"price_per_share":0,"usd_value":0,"security_title":"Common stock","importance":15},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — AGIOS PHARMACEUTICALS, INC. — 2026-06-23","url_slug":"/sec/cik-0001439222/4/0001439222-26-000079","accession_number":"0001439222-26-000079","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — AGIOS PHARMACEUTICALS, INC. — 2026-06-23","url_slug":"/sec/cik-0001439222/4/0001439222-26-000081","accession_number":"0001439222-26-000081","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — AGIOS PHARMACEUTICALS, INC. — 2026-06-23","url_slug":"/sec/cik-0001439222/4/0001439222-26-000083","accession_number":"0001439222-26-000083","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — AGIOS PHARMACEUTICALS, INC. — 2026-06-23","url_slug":"/sec/cik-0001439222/4/0001439222-26-000085","accession_number":"0001439222-26-000085","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — AGIOS PHARMACEUTICALS, INC. — 2026-06-23","url_slug":"/sec/cik-0001439222/4/0001439222-26-000087","accession_number":"0001439222-26-000087","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — AGIOS PHARMACEUTICALS, INC. — 2026-06-23","url_slug":"/sec/cik-0001439222/4/0001439222-26-000089","accession_number":"0001439222-26-000089","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — AGIOS PHARMACEUTICALS, INC. — 2026-06-23","url_slug":"/sec/cik-0001439222/4/0001439222-26-000091","accession_number":"0001439222-26-000091","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — AGIOS PHARMACEUTICALS, INC. — 2026-06-23","url_slug":"/sec/cik-0001439222/4/0001439222-26-000093","accession_number":"0001439222-26-000093","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — AGIOS PHARMACEUTICALS, INC. — 2026-06-23","url_slug":"/sec/cik-0001439222/4/0001439222-26-000095","accession_number":"0001439222-26-000095","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — AGIOS PHARMACEUTICALS, INC. — 2026-06-23","url_slug":"/sec/cik-0001439222/4/0001439222-26-000097","accession_number":"0001439222-26-000097","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — AGIOS PHARMACEUTICALS, INC. — 2026-06-23","url_slug":"/sec/cik-0001439222/4/0001439222-26-000099","accession_number":"0001439222-26-000099","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — AGIOS PHARMACEUTICALS, INC. — 2026-06-23","url_slug":"/sec/cik-0001439222/4/0001439222-26-000107","accession_number":"0001439222-26-000107","importance":30},{"ts":"2026-06-18","kind":"sec.filing","form_type":"8-K","title":"8-K — AGIOS PHARMACEUTICALS, INC. — 2026-06-18","url_slug":"/sec/cik-0001439222/8-k/0001193125-26-275879","accession_number":"0001193125-26-275879","importance":35},{"ts":"2026-06-18","kind":"sec.filing","form_type":"S-8","title":"S-8 — AGIOS PHARMACEUTICALS, INC. — 2026-06-18","url_slug":"/sec/cik-0001439222/s-8/0001193125-26-275895","accession_number":"0001193125-26-275895","importance":30},{"ts":"2026-06-18","kind":"sec.insider.m","reporter":"CAPELLO JEFFREY D","title":null,"shares":2816,"price_per_share":0,"usd_value":0,"security_title":"Common stock","importance":15},{"ts":"2026-06-18","kind":"sec.insider.m","reporter":"Foster-Cheek Kaye I","title":null,"shares":2816,"price_per_share":0,"usd_value":0,"security_title":"Common stock","importance":15},{"ts":"2026-06-18","kind":"sec.insider.m","reporter":"FOUSE JACQUALYN A","title":"","shares":2816,"price_per_share":0,"usd_value":0,"security_title":"Common stock","importance":15},{"ts":"2026-06-18","kind":"sec.insider.m","reporter":"Smith Cynthia","title":null,"shares":2816,"price_per_share":0,"usd_value":0,"security_title":"Common stock","importance":15},{"ts":"2026-06-18","kind":"sec.insider.m","reporter":"Scadden David","title":null,"shares":2816,"price_per_share":0,"usd_value":0,"security_title":"Common stock","importance":15},{"ts":"2026-06-18","kind":"sec.insider.m","reporter":"Owen Adams Catherine","title":null,"shares":2816,"price_per_share":0,"usd_value":0,"security_title":"Common stock","importance":15},{"ts":"2026-06-18","kind":"sec.insider.m","reporter":"Ho Maykin","title":null,"shares":2816,"price_per_share":0,"usd_value":0,"security_title":"Common stock","importance":15},{"ts":"2026-06-18","kind":"sec.insider.m","reporter":"Ballal Rahul D.","title":null,"shares":2816,"price_per_share":0,"usd_value":0,"security_title":"Common stock","importance":15},{"ts":"2026-06-16","kind":"sec.filing","form_type":"4","title":"4 — AGIOS PHARMACEUTICALS, INC. — 2026-06-16","url_slug":"/sec/cik-0001439222/4/0001439222-26-000077","accession_number":"0001439222-26-000077","importance":30},{"ts":"2026-06-13","kind":"sec.insider.m","reporter":"CAPELLO JEFFREY D","title":null,"shares":1976,"price_per_share":0,"usd_value":0,"security_title":"Common stock","importance":15},{"ts":"2026-06-13","kind":"sec.insider.m","reporter":"Owen Adams Catherine","title":null,"shares":1976,"price_per_share":0,"usd_value":0,"security_title":"Common stock","importance":15},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — AGIOS PHARMACEUTICALS, INC. — 2026-05-15","url_slug":"/sec/cik-0001439222/schedule-13g-a/0001172661-26-002118","accession_number":"0001172661-26-002118","importance":30},{"ts":"2026-05-01","kind":"clinical.trial","reporter":"Agios Pharmaceuticals, Inc.","title":"A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency","security_title":"PHASE2","status":"COMPLETED","accession_number":"NCT02476916","excerpt":"[\"Pyruvate Kinase Deficiency\"]","importance":45},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Agios Pharmaceuticals, Inc.","title":"A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07075640","excerpt":"[\"Healthy Participants\"]","importance":30},{"ts":"2026-04-24","kind":"clinical.trial","reporter":"Agios Pharmaceuticals, Inc.","title":"A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05175105","excerpt":"[\"Pediatric Pyruvate Kinase Deficiency\",\"Pediatric Hemolytic Anemia\"]","importance":60},{"ts":"2026-04-24","kind":"clinical.trial","reporter":"Agios Pharmaceuticals, Inc.","title":"A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04770779","excerpt":"[\"Transfusion-dependent Alpha-Thalassemia\",\"Transfusion-dependent Beta-Thalassemia\"]","importance":60},{"ts":"2026-04-23","kind":"clinical.trial","reporter":"Agios Pharmaceuticals, Inc.","title":"A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)","security_title":"PHASE2,PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05031780","excerpt":"[\"Sickle Cell Disease\"]","importance":60},{"ts":"2026-04-23","kind":"clinical.trial","reporter":"Agios Pharmaceuticals, Inc.","title":"Pyruvate Kinase Deficiency Global Longitudinal Registry","security_title":null,"status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT03481738","excerpt":"[\"Pyruvate Kinase Deficiency\"]","importance":25}]}